Proliferating cell nuclear antigen directly interacts with androgen receptor and enhances androgen receptor‑mediated signaling

Lu,Shan; Dong,Zhongyun

doi:10.3892/ijo.2021.5221

Proliferating cell nuclear antigen directly interacts with androgen receptor and enhances androgen receptor‑mediated signaling

Authors:
- Shan Lu
- Zhongyun Dong
View Affiliations

Affiliations: Division of Hematology‑Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
Published online on: May 13, 2021 https://doi.org/10.3892/ijo.2021.5221
Article Number: 41

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Androgen receptor (AR) and/or its constitutively active splicing variants (AR‑Vs), such as AR‑V7 and ARv567es, is required for prostate cancer cell growth and survival, and cancer progression. Proliferating cell nuclear antigen (PCNA) is preferentially overexpressed in all cancers and executes its functions through interaction with numerous partner proteins. The aim of the present study was to investigate the potential role of PCNA in the regulation of AR activity. An identical consensus sequence of the PCNA‑interacting protein‑box (PIP‑box) was identified at the N‑terminus of human, mouse and rat AR proteins. It was found that PCNA complexes with the full‑length AR (AR‑FL) and AR‑V7, which can be attenuated by the small molecule PIP‑box inhibitor, T2AA. PCNA also complexes with ARv567es and recombinant AR protein. The PCNA inhibitors, PCNA‑I1S and T2AA, inhibited AR transcriptional activity and the expression of AR target genes in LNCaP‑AI and 22Rv1 cells, but not in AR‑negative PC‑3 cells. The knockdown of PCNA expression reduced dihydrotestosterone‑stimulated AR transcriptional activity and abolished the inhibitory effect of PCNA‑I1S on AR activity. The PCNA inhibitor, PCNA‑I1, exerted additive growth inhibitory effects with androgen deprivation and enzalutamide in cells expressing AR‑FL or AR‑FL/AR‑V7, but not in AR‑negative PC‑3 cells. Finally, R9‑AR‑PIP, a small peptide mimicking AR PIP‑box, was found to bind to GFP‑PCNA at K_d of 2.73 µM and inhibit the expression of AR target genes, AR transcriptional activity and the growth of AR‑expressing cells. On the whole, these data strongly suggest that AR is a PCNA partner protein and interacts with PCNA via the PIP‑box and that targeting the PCNA‑AR interaction may represent an innovative and selective therapeutic strategy against prostate cancer, particularly castration‑resistant prostate cancers overexpressing constitutively active AR‑Vs.

View Figures

View References

1	Tsai MJ and O'Malley BW: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Ann Rev Biochem. 63:451–486. 1994. View Article : Google Scholar : PubMed/NCBI
2	Mangelsdorf DJ and Evans RM: The RXR heterodimers and orphan receptors. Cell. 83:841–850. 1995. View Article : Google Scholar : PubMed/NCBI
3	Biron E and Bedard F: Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer. J Steroid Biochem Mol Biol. 161:36–44. 2016. View Article : Google Scholar
4	Dehm SM and Tindall DJ: Alternatively spliced androgen receptor variants. Endocr Relat Cancer. 18:R183–R196. 2011. View Article : Google Scholar : PubMed/NCBI
5	Lu J, Van der Steen T and Tindall DJ: Are androgen receptor variants a substitute for the full-length receptor? Nat Rev Urol. 12:137–144. 2015. View Article : Google Scholar : PubMed/NCBI
6	Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C and Balk SP: Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res. 20:1590–1600. 2014. View Article : Google Scholar : PubMed/NCBI
7	Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, et al: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 371:1028–1038. 2014. View Article : Google Scholar : PubMed/NCBI
8	Yin Y, Li R, Xu K, Ding S, Li J, Baek G, Ramanand SG, Ding S, Liu Z, Gao Y, et al: Androgen receptor variants mediate DNA repair after prostate cancer irradiation. Cancer Res. 77:4745–4754. 2017. View Article : Google Scholar : PubMed/NCBI
9	Xu D, Zhan Y, Qi Y, Cao B, Bai S, Xu W, Gambhir SS, Lee P, Sartor O, Flemington EK, et al: Androgen receptor splice variants dimerize to transactivate target genes. Cancer Res. 75:3663–3671. 2015. View Article : Google Scholar : PubMed/NCBI
10	Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, et al: Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 72:3457–3462. 2012. View Article : Google Scholar : PubMed/NCBI
11	Wach S, Taubert H and Cronauer M: Role of androgen receptor splice variants, their clinical relevance and treatment options. World J Urol. 38:647–656. 2020. View Article : Google Scholar
12	Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, et al: A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 69:2305–2313. 2009. View Article : Google Scholar : PubMed/NCBI
13	Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, Russo JW, Figueiredo I, Bertan C, Seed G, et al: Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J Clin Invest. 129:192–208. 2019. View Article : Google Scholar :
14	Honda M, Kimura T, Kamata Y, Tashiro K, Kimura S, Koike Y, Sato S, Yorozu T, Furusato B, Takahashi H, et al: Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence. Prostate. 79:1043–1052. 2019. View Article : Google Scholar : PubMed/NCBI
15	Paschalis A, Sharp A, Welti JC, Neeb A, Raj GV, Luo J, Plymate SR and de Bono JS: Alternative splicing in prostate cancer. Nature Rev Clin Oncol. 15:663–675. 2018. View Article : Google Scholar
16	Scher HI, Graf RP, Schreiber NA, Jayaram A, Winquist E, McLaughlin B, Lu D, Fleisher M, Orr S, Lowes L, et al: Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer. JAMA Oncol. 4:1179–1186. 2018. View Article : Google Scholar : PubMed/NCBI
17	Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, et al: Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 120:2715–2730. 2010. View Article : Google Scholar : PubMed/NCBI
18	Van Etten JL, Nyquist M, Li Y, Yang R, Ho Y, Johnson R, Ondigi O, Voytas DF, Henzler C and Dehm SM: Targeting a single alternative polyadenylation site coordinately blocks expression of androgen receptor mRNA splice variants in prostate cancer. Cancer Res. 77:5228–5235. 2017. View Article : Google Scholar : PubMed/NCBI
19	Yang YC, Banuelos CA, Mawji NR, Wang J, Kato M, Haile S, McEwan IJ, Plymate S and Sadar MD: Targeting androgen receptor activation Function-1 with EPI to overcome resistance mechanisms in castration-resistant prostate cancer. Clin Cancer Res. 22:4466–4477. 2016. View Article : Google Scholar : PubMed/NCBI
20	Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP and Gao AC: Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res. 20:3198–3210. 2014. View Article : Google Scholar : PubMed/NCBI
21	Moldovan GL, Pfander B and Jentsch S: PCNA, the maestro of the replication fork. Cell. 129:665–679. 2007. View Article : Google Scholar : PubMed/NCBI
22	Stoimenov I and Helleday T: PCNA on the crossroad of cancer. Biochem Soc Transact. 37:605–613. 2009. View Article : Google Scholar
23	Maga G and Hubscher U: Proliferating cell nuclear antigen (PCNA): A dancer with many partners. J Cell Sci. 116:3051–3060. 2003. View Article : Google Scholar : PubMed/NCBI
24	Gilljam KM, Feyzi E, Aas PA, Sousa MM, Muller R, Vagbo CB, Catterall TC, Liabakk NB, Slupphaug G, Drabløs F, et al: Identification of a novel, widespread, and functionally important PCNA-binding motif. J Cell Biol. 186:645–654. 2009. View Article : Google Scholar : PubMed/NCBI
25	Gulbis JM, Kelman Z, Hurwitz J, O'Donnell M and Kuriyan J: Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human PCNA. Cell. 87:297–306. 1996. View Article : Google Scholar : PubMed/NCBI
26	Lu S, Lee J, Revelo M, Wang X and Dong Z: Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice. Clin Cancer Res. 13:5692–5702. 2007. View Article : Google Scholar : PubMed/NCBI
27	Spires SE, Banks ER, Davey DD, Jennings CD, Wood DP Jr and Cibull ML: Proliferating cell nuclear antigen in prostatic adenocarcinoma: Correlation with established prognostic indicators. Urology. 43:660–666. 1994. View Article : Google Scholar : PubMed/NCBI
28	Kallakury BV, Sheehan CE, Rhee SJ, Fisher HA, Kaufman RP Jr, Rifkin MD and Ross JS: The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: A comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2. Cancer. 85:1569–1576. 1999. View Article : Google Scholar : PubMed/NCBI
29	Muller R, Misund K, Holien T, Bachke S, Gilljam KM, Vatsveen TK, Ro TB, Bellacchio E, Sundan A and Otterlei M: Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells. PLoS One. 8:e704302013. View Article : Google Scholar : PubMed/NCBI
30	Smith SJ, Gu L, Phipps EA, Dobrolecki L, Mabrey KS, Gulley P, Dillehay KL, Dong Z, Fields GB, Chen Y, et al: A peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer. Mol Pharmacol. 87:263–276. 2015. View Article : Google Scholar :
31	Punchihewa C, Inoue A, Hishiki A, Fujikawa Y, Connelly M, Evison B, Shao Y, Heath R, Kuraoka I, Rodrigues P, et al: Identification of a small molecule PCNA inhibitor that disrupts interactions with PIP-Box proteins and inhibits DNA replication. J Biol Chem. 287:14289–14300. 2012. View Article : Google Scholar : PubMed/NCBI
32	Gu L, Lingeman R, Yakushijin F, Sun E, Cui Q, Chao J, Hu W, Li H, Hickey RJ, Stark JM, et al: The anticancer activity of a First-in-class Small-molecule targeting PCNA. Clin Cancer Res. 24:6053–6065. 2018. View Article : Google Scholar : PubMed/NCBI
33	Lu S and Dong Z: Additive effects of a small molecular PCNA inhibitor PCNA-I1S and DNA damaging agents on growth inhibition and DNA damage in prostate and lung cancer cells. PLoS One. 14:e02238942019. View Article : Google Scholar
34	Dillehay KL, Seibel WL, Zhao D, Lu S and Dong Z: Target validation and structure-activity analysis of a series of novel PCNA inhibitors. Pharmacol Res Perspect. 3:e001152015. View Article : Google Scholar : PubMed/NCBI
35	Dillehay KL, Lu S and Dong Z: Antitumor effects of a novel small molecule targeting PCNA chromatin association in prostate cancer. Mol Cancer Ther. 13:2817–2826. 2014. View Article : Google Scholar : PubMed/NCBI
36	Tan Z, Wortman M, Dillehay KL, Seibel WL, Evelyn CR, Smith SJ, Malkas LH, Zheng Y, Lu S and Dong Z: Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth. Mol Pharmacol. 81:811–819. 2012. View Article : Google Scholar : PubMed/NCBI
37	Murthy S, Wu M, Bai VU, Hou Z, Menon M, Barrack ER, Kim SH and Reddy GP: Role of androgen receptor in progression of LNCaP prostate cancer cells from G1 to S phase. PLoS One. 8:e566922013. View Article : Google Scholar : PubMed/NCBI
38	Lu S, Tsai SY and Tsai MJ: Melecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. Endocrinology. 140:5054–5059. 1999. View Article : Google Scholar : PubMed/NCBI
39	Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KA, Voytas DF and Dehm SM: TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci USA. 110:17492–17497. 2013. View Article : Google Scholar : PubMed/NCBI
40	Dong Z, Liu Y, Scott KF, Levin L, Gaitonde K, Bracken RB, Burk B, Zhai Q, Wang J, Oleksowicz L and Lu S: Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for Prostate Cancer. Carcinogenesis. 31:1948–1955. 2010. View Article : Google Scholar : PubMed/NCBI
41	Lu S and Dong Z: Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER/ERBB-elicited signaling in lung and prostate cancer cells. Int J Oncol. 50:2113–2122. 2017. View Article : Google Scholar : PubMed/NCBI
42	Lu S, Tan Z, Wortman M, Lu S and Dong Z: Regulation of heat shock protein 70-1 expression by androgen receptor and its signaling in human prostate cancer cells. Int J Oncol. 36:459–467. 2010.PubMed/NCBI
43	Simon P: Q-Gene: Processing quantitative real-time RT-PCR data. Bioinformatics. 19:1439–1440. 2003. View Article : Google Scholar : PubMed/NCBI
44	Dong ZY, Ward NE, Fan D, Gupta KP and O'Brian CA: In vitro model for intrinsic drug resistance: Effects of protein kinase C activators on the chemosensitivity of cultured human colon cancer cells. Mol Pharmacol. 39:563–569. 1991.PubMed/NCBI
45	Khavrutskii L, Yeh J, Timofeeva O, Tarasov SG, Pritt S, Stefanisko K and Tarasova N: Protein purification-free method of binding affinity determination by microscale thermophoresis. J Vis Exp. 50541:2013.
46	Leonhardt H, Rahn HP, Weinzierl P, Sporbert A, Cremer T, Zink D and Cardoso MC: Dynamics of DNA replication factories in living cells. J Cell Biol. 149:271–280. 2000. View Article : Google Scholar : PubMed/NCBI
47	Slade D: Maneuvers on PCNA Rings during DNA replication and repair. Genes (Basel). 9:4162018. View Article : Google Scholar
48	Chen Z, Wu D, Thomas-Ahner JM, Lu C, Zhao P, Zhang Q, Geraghty C, Yan PS, Hankey W, Sunkel B, et al: Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. Proc Natl Acad Sci USA. 115:6810–6815. 2018. View Article : Google Scholar : PubMed/NCBI
49	Lu S, Liu M, Epner DE, Tsai SY and Tsai MJ: Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol. 13:376–384. 1999. View Article : Google Scholar : PubMed/NCBI
50	Dai JL, Maiorino CA, Gkonos PJ and Burnstein KL: Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells. Steroids. 61:531–539. 1996. View Article : Google Scholar : PubMed/NCBI
51	Manin M, Baron S, Goossens K, Beaudoin C, Jean C, Veyssiere G, Verhoeven G and Morel L: Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J. 366:729–736. 2002. View Article : Google Scholar : PubMed/NCBI
52	Jia L and Coetzee GA: Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus. Cancer Res. 65:8003–8008. 2005. View Article : Google Scholar : PubMed/NCBI
53	Krishna TS, Kong XP, Gary S, Burgers PM and Kuriyan J: Crystal structure of the eukaryotic DNA polymerase processivity factor PCNA. Cell. 79:1233–1243. 1994. View Article : Google Scholar : PubMed/NCBI
54	Kelman Z and O'Donnell M: Structural and functional similarities of prokaryotic and eukaryotic DNA polymerase sliding clamps. Nucleic Acids Res. 23:3613–3620. 1995. View Article : Google Scholar : PubMed/NCBI
55	Koryakina Y, Ta HQ and Gioeli D: Androgen receptor phosphorylation: Biological context and functional consequences. Endocr Relat Cancer. 21:T131–T145. 2014. View Article : Google Scholar : PubMed/NCBI
56	Dong Z, Liu Y and Lu S, Wang A, Lee K, Wang LH, Revelo M and Lu S: Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endocrinol. 20:2315–2325. 2006. View Article : Google Scholar : PubMed/NCBI